Associated between insertion/deletion polymorphism of MDM2 and risk of breast cancer in an Iranian population

Publish Year: 1393
نوع سند: مقاله کنفرانسی
زبان: English
View: 1,060

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

CIGS13_0489

تاریخ نمایه سازی: 7 بهمن 1393

Abstract:

Background: MDM2 (Murine Double Minute-2) is an oncoprotein that inhibits the P53 activity.Overexpression of MDM2 gene has been reported in several human tumors. In the present study we aimed to evaluate the impact of 40-bp insertion/deletion (ins/del) polymorphism in the promoter ofMDM2 and susceptibility to breast cancer in a sample of Iranian population. Methods: This case-control study was done on 236 patients with breast cancer and 203 healthy individuals. The 40-bp ins/del polymorphism was determined by using polymerase chain reaction method.Results: The findings indicated that MDM2 ins/del variant increased the risk of breast cancer in codominant (OR=2.09, 95%CI=1.14-3.85, P=0.018, del/del vs ins/ins), dominant (OR=1.49, 95%CI=1.02-2.18, P=0.038, ins/del+del/del vs ins/ins) and recessive (OR=1.86, 95%CI=1.03-3.34, P=0.038, del/del vs ins/ins+ins/del) tested inheritance models. The del allele increased the risk of breast cancer (OR= 1.48, 95% CI=1.11-1.98, P=0.008) compared with ins allele.Conclusions: Our result revealed that 40-bp ins/del polymorphism in the promoter of MDM2 increased the risk of breast cancer in an Iranian population. Further investigations with larger sample sizes and diverse ethnicities are needed to verify our findings.

Authors

Mohsen Omrani

Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences,Zahedan, Iran

Mohammad Hashemi

Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences,Zahedan, Iran

Ebrahim Eskandari-Nasab

Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences,Zahedan, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Ma Y, Bian J, Cao H. MDM2 SNP309 rs2279744 polymorphism ...
  • Dong D, Gao X, Zhu Z, Yu Q, Bian S, ...
  • Hu Z, Ma H, Lu D, Qian J, Zhou J, ...
  • Ma H, Hu Z, Zhai X, Wang S, Wang X, ...
  • Hashemi M, E skandari-Nas ab E, Fazaeli A, Rezaei H, ...
  • Hashemi M, Mo azeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani ...
  • Harris SL, Levine AJ. The p53 pathway: positive and negative ...
  • Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, ...
  • Bond GL, Hu W, Levine AJ. MDM2 is a central ...
  • Kubbutat MH, Jones SN, Vousden Kl Regulation of p53 stability ...
  • Momand J, Zambetti GP, Olson DC, George D, Levine AJ. ...
  • Meddeb M, Valent A, Danglot G, Nguyen VC, Duverger A, ...
  • Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, ...
  • Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, ...
  • Bond GL, Hu W, Levine A. A single nucleotide polymorphism ...
  • Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, ...
  • Wagner K, Hemminki K, Grzybowska E, Klaes R, Burwinkel B, ...
  • نمایش کامل مراجع